ABM 125

Drug Profile

ABM 125

Alternative Names: ABM125; Anti-IL-25 mAb

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator Abeome Corporation
  • Class Antiasthmatics; Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma; Atopic dermatitis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 21 Apr 2017 ABM 125 is available for licensing as of 21 Apr 2017. http://abeomecorp.com (Abeome pipeline, April 2017)
  • 21 Apr 2017 Preclinical trials in Asthma in USA (Intraperitoneal) (Abeome pipeline, April 2017)
  • 21 Apr 2017 Preclinical trials in Atopic dermatitis in USA (Intraperitoneal) (Abeome pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top